CASI Pharmaceuticals (CASI) Competitors $1.30 -0.03 (-1.90%) As of 12:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CASI vs. ONCY, MCRB, PYRGF, ANEB, MNOV, IMMX, VHAQ, ANRO, ACHL, and RPTXShould you be buying CASI Pharmaceuticals stock or one of its competitors? The main competitors of CASI Pharmaceuticals include Oncolytics Biotech (ONCY), Seres Therapeutics (MCRB), PyroGenesis Canada (PYRGF), Anebulo Pharmaceuticals (ANEB), MediciNova (MNOV), Immix Biopharma (IMMX), Viveon Health Acquisition (VHAQ), Alto Neuroscience (ANRO), Achilles Therapeutics (ACHL), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical products" industry. CASI Pharmaceuticals vs. Its Competitors Oncolytics Biotech Seres Therapeutics PyroGenesis Canada Anebulo Pharmaceuticals MediciNova Immix Biopharma Viveon Health Acquisition Alto Neuroscience Achilles Therapeutics Repare Therapeutics CASI Pharmaceuticals (NASDAQ:CASI) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership. Does the media prefer CASI or ONCY? In the previous week, Oncolytics Biotech had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Oncolytics Biotech and 1 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled Oncolytics Biotech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CASI Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncolytics Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CASI or ONCY more profitable? Oncolytics Biotech has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -129.05%. Oncolytics Biotech's return on equity of -313.77% beat CASI Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CASI Pharmaceuticals-129.05% -972.55% -77.33% Oncolytics Biotech N/A -313.77%-130.19% Which has more risk & volatility, CASI or ONCY? CASI Pharmaceuticals has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Do institutionals & insiders have more ownership in CASI or ONCY? 22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher earnings and valuation, CASI or ONCY? Oncolytics Biotech has lower revenue, but higher earnings than CASI Pharmaceuticals. Oncolytics Biotech is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCASI Pharmaceuticals$28.54M0.56-$39.26M-$2.55-0.51Oncolytics BiotechN/AN/A-$23.14M-$0.29-3.14 Do analysts prefer CASI or ONCY? CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 206.51%. Oncolytics Biotech has a consensus target price of $4.33, suggesting a potential upside of 375.67%. Given Oncolytics Biotech's higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than CASI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryOncolytics Biotech beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get CASI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CASI vs. The Competition Export to ExcelMetricCASI PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.05M$2.42B$5.50B$9.03BDividend YieldN/A1.77%5.39%4.11%P/E Ratio-0.518.9627.5220.10Price / Sales0.56468.23397.84108.06Price / CashN/A151.5836.1356.90Price / Book10.884.627.985.65Net Income-$39.26M$31.34M$3.16B$248.47M7 Day Performance0.38%0.65%1.91%2.80%1 Month Performance-27.70%7.60%4.17%5.62%1 Year Performance-75.14%1.55%35.76%21.20% CASI Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CASICASI Pharmaceuticals4.5987 of 5 stars$1.31-1.9%$4.00+206.5%-75.4%$16.05M$28.54M-0.51180News CoverageONCYOncolytics Biotech1.5461 of 5 stars$0.64-7.7%$4.33+580.3%-20.5%$65.07MN/A-2.2030MCRBSeres Therapeutics3.6456 of 5 stars$7.42+0.3%$73.67+892.8%-22.5%$64.62M$126.32M-1.61330Positive NewsPYRGFPyroGenesis Canada0.0899 of 5 stars$0.34-1.7%N/A-35.5%$64.37M$9.14M-5.7590News CoverageANEBAnebulo Pharmaceuticals2.1843 of 5 stars$1.52-1.3%$5.50+261.8%-27.3%$63.27MN/A-5.854MNOVMediciNova1.8461 of 5 stars$1.31+1.6%$7.00+434.4%-9.3%$63.27M$1M-5.7010IMMXImmix Biopharma3.6888 of 5 stars$2.23-0.4%$7.00+213.9%+23.0%$62.44MN/A-3.199Gap UpVHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeANROAlto Neuroscience2.3794 of 5 stars$2.37+5.1%$8.50+259.4%-79.0%$60.91MN/A-1.01N/AACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250RPTXRepare Therapeutics2.5165 of 5 stars$1.41flat$4.50+219.1%-55.6%$60.48M$53.48M-0.47180 Related Companies and Tools Related Companies Oncolytics Biotech Competitors Seres Therapeutics Competitors PyroGenesis Canada Competitors Anebulo Pharmaceuticals Competitors MediciNova Competitors Immix Biopharma Competitors Viveon Health Acquisition Competitors Alto Neuroscience Competitors Achilles Therapeutics Competitors Repare Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CASI) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
